


TOTAL SYNTHESSES OF THE DITERPENOIDS (-)-KOLAVENOL AND (-)-AGELASINE B

Edward Piers* and Jacques Y. Roberge

Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver,
British Columbia, Canada, V6T 1Z1

Summary: The *trans*-clerodane diterpenoids (-)-kolavenol (2) and (-)-agelasine B (1) have been prepared from the enantiomerically pure decalone 3. The key steps of the syntheses involve the stereoselective alkylation of the nitrile 4 (to give 5), the efficient coupling of the iodides 10 and 11 to produce the clerodane skeleton 12, and the electrochemical reduction of 16 to provide (-)-1.


The natural product (-)-agelasine B (1) is a structurally unusual compound of mixed biogenesis. Isolated from the Okinawan marine sponge *Agelas nakamura* Hoshino,¹ this substance contains a 9-methyl-7-adeninium moiety attached to C-15 of a *trans*-clerodane diterpenoid skeleton and, interestingly, has been shown to possess a variety of biological activities, including antimicrobial




activity and inhibitory effects on Na,K-ATPase.¹ We report herein a total synthesis of (-)-1 and of (-)-kolavenol (2), a *trans*-clerodane diterpenoid isolated from the oleoresin of *Hardwickia pinnata* Roxb.²

Reaction of the enantiomerically pure *cis*-fused decalone 3³ (see Scheme 1) with (*p*-tolylsulfonyl)methyl isocyanide (TosMIC) in 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (DMPU) in the presence of base provided the nitrile 4 (mixture of epimers).⁴ Under these reaction conditions, the process that introduced the necessary nitrile function was preceded by a thermodynamically favored, base-promoted equilibration (epimerization) of the two carbon centers adjacent to the carbonyl group in 3. Thus, compound 4, which possesses three of the four stereogenic centers with the correct absolute configuration for the eventual syntheses of 1 and 2, was readily obtained.

Alkylation of the anion 17 derived from 4 with ICH₂CH₂OCH₂OMe is expected to occur, for steric reasons, from the side of the molecule opposite to the angular methyl group. Indeed, this process gave a single product 5 ([α]_D²⁵ +56.9°) in high yield. Reduction of 5 with *t*-Bu₂AlH in 1,2-dimethoxyethane (DME), followed by acid hydrolysis of the resulting imine, gave the somewhat unstable aldehyde 6, which upon subjection to a modified Huang-Minlon reduction procedure, gave 7 ([α]_D²⁵ +75.7°). Thus, the final stereogenic (quaternary) center was installed stereoselectively and efficiently.






Scheme 1 a: TosMIC, *t*-BuOK, *t*-BuOH, DMPU, 45°C, 95 h; **b:** *i*-Pr₂NLi, HMPA, THF, -78°C to 0°C; ICH₂CH₂OCH₂OMe; **c:** *i*-Bu₂AlH, DME, 60°C, 6 h; AcOH, THF, H₂O, r.t., 12 h; **d:** H₂NNH₂ (anhydrous), (HOCH₂CH₂)₂O, 120-150°C, 4.5 h; remove H₂O, excess H₂NNH₂ (vacuum pump); add KOH (10 equiv), heat 230°C, 10 h; **e:** Me₂BBr, CH₂Cl₂, -78°C, 3 h; NaHCO₃, Na₂CO₃, H₂O, DME, r.t., 6 h; **f:** *p*-TsOH, CHCl₃, r.t., 24 h; **g:** I₂, Ph₃P, imidazole, CH₂Cl₂, r.t., 24 h; **h:** *t*-BuLi (2.3 equiv), Et₂O, -78°C to r.t.; recool to -78°C; add ZnBr₂ (1.5 equiv) in THF, -78°C to r.t.; add Pd(dba)₂ (0.03 equiv), Ph₃As (0.12 equiv), and 11 (1.5 equiv), stir r.t., 21 h; **i:** Bu₄NF, THF; **j:** Ph₃PBr₂, CH₂Cl₂; **k:** 14 (2 equiv), Bu₄Ni, DMA, 60°C; **l:** -1.0 V, Hg(vs. Ag/AgCl), divided cell, NaOAc buffer, pH 4.5, H₂O; NaCl, H₂O.

Sequential treatment of 7 with Me₂BBr in CH₂Cl₂⁵ and NaHCO₃-Na₂CO₃ in aqueous DME⁶ provided a mixture of the alkenes 8 and 9 and, therefore, it was clear that during the Me₂BBr-mediated removal of the MOM group, partial isomerization of the exocyclic double bond had occurred.⁷ Treatment of 8 with *p*-TsOH in CHCl₃ completed the rearrangement process and provided an excellent yield of the alcohol 9 ([α]_D²⁵ -48.7°), which was readily transformed⁸ into the corresponding iodide 10.

Completion of the synthesis of the *trans*-clerodane carbon skeleton was accomplished *via* an efficient, convergent route involving an overall coupling of **10** with the vinyl iodide **11**. The latter substance was prepared from ethyl 2-butyrate **18** (Scheme 2). Reaction of **18** with lithium (trimethylstannyl)(cyano)cuprate in the presence of EtOH⁹ provided, stereoselectively, the (*E*)-enoate **19**. Transformation of this material into the required iodo alkene **11** was carried out, *via* the intermediates **20** and **21**, in a straightforward fashion.



Scheme 2 a: $(\text{Me}_3\text{SnCuCN})\text{Li}$, THF, EtOH, -78°C ; b: $t\text{-Bu}_2\text{AlH}$, Et_2O , -78°C to 0°C ; c: $(i\text{-Pr})_3\text{SiCl}$, imidazole, CH_2Cl_2 ; d: I_2 , CH_2Cl_2 .

Treatment of **10** with $t\text{-BuLi}$ at low temperature¹⁰ was followed by conversion of the resultant primary alkyl-lithium into the corresponding organozinc reagent. Linking of the latter species with **11** was achieved by use of palladium(0)bis(dibenzylidene)acetone $[\text{Pd}(\text{dba})_2]$ in the presence of triphenylarsine.¹¹ This synthetically useful, Pd(0)-catalyzed coupling process provided the silyl ether **12**, which was readily transformed into the natural product (-)-kolavenol (**2**).¹²

Reaction of the silyl ether **12** with Ph_3PBr_2 in CH_2Cl_2 ¹³ provided directly the allylic bromide **13** (unstable on silica gel), which, upon treatment with N^6 -methoxy-9-methyladenine (**14**)^{14,15} in N,N -dimethylacetamide (DMA) gave a mixture of the neutral compound **15** and the desired salt **16**. Analysis of the crude product by ^1H NMR spectroscopy showed that **15** and **16** were formed in a ratio of ~4:5.¹⁶ Separation of these substances by chromatography on silica gel provided homogenous **16** (mp $198\text{--}199^\circ\text{C}$, $[\alpha]_{\text{D}}^{25} -24.4^\circ$; lit.¹⁵ mp $192\text{--}196^\circ\text{C}$, $[\alpha]_{\text{D}}^{21} -26.2^\circ$).

Conversion of **16** into (-)-agelasine B (**1**) required reductive cleavage of the N-O bond associated with the methoxyamino group. This transformation was conveniently achieved by use of an electrochemical process.¹⁷ Thus, reduction (0.1 M NaOAc, H_2O , pH 4.5) of **16** at -1.0 V (vs. Ag/AgCl) using a mercury electrode, followed by anion exchange with NaCl and careful purification of the product by chromatography on silica gel (4:1 $\text{CH}_2\text{Cl}_2\text{-MeOH}$) gave (-)-agelasine B (**1**) in 53% yield. This material exhibited $[\alpha]_{\text{D}}^{25} -27.2^\circ$ (lit. -21.5° , -34.8° ¹⁵) and displayed spectra (^1H NMR, ^{13}C NMR, IR, UV) identical with those of natural (-)-agelasine B.¹⁸

Acknowledgements: We are grateful to FCAR (Québec) and UBC for postgraduate scholarships to J.Y.R. and to Merck Frosst Canada Inc. and NSERC (Canada) for financial support.

References and notes:

1. Nakamura, H.; Wu, H.; Ohizumi, Y.; Hirata, Y. *Tetrahedron Lett.* **1984**, *25*, 2989; Wu, H.; Nakamura, H.; Kobayashi, J.; Kobayashi, M.; Ohizumi, Y.; Hirata, Y. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 2495.
2. Misra, R.; Pandey, R. C.; Dev, S. *Tetrahedron*, **1979**, *35*, 985.
3. Piers, E.; Roberge, J. Y. *Tetrahedron Lett.* **1991**, *32*, 5219.
4. All compounds reported herein exhibited spectra in accord with structural assignments and gave satisfactory C and H analyses.
5. Guindon, Y.; Yoakim, C.; Morton, H. E. *J. Org. Chem.* **1984**, *49*, 3912.
6. The crude product from the Me₂BBr reaction contained some of the bromomethyl ether of **8**. Aqueous base was employed to convert this material into **8**.
7. It is likely that the presence of traces of acid in the Me₂BBr was responsible for this (partial) isomerization.
8. Garegg, P. J.; Samuelsson, B. *J. Chem. Soc., Chem. Commun.* **1979**, 978.
9. Piers, E.; Wong, T.; Ellis, K. A. *Can J. Chem.* **1992**, in press.
10. Bailey, W. F.; Punzalan, E. R. *J. Org. Chem.* **1990**, *55*, 5404; Negishi, E.; Swanson, D. R.; Rousset, C. J. *J. Org. Chem.* **1990**, *55*, 5406.
11. Cf. Farina, V.; Krishnan, B. *J. Am. Chem. Soc.* **1991**, *113*, 9585.
12. Our synthetic material ($[\alpha]_D^{25} -56.3^\circ$; lit.² $[\alpha]_D^{25} -45.7^\circ$) was spectrally identical with a sample of (-)-kolavenol obtained by reduction of methyl kolavenate. We thank Professor T. Tokoroyama for a sample of this ester. See Iio, H.; Monden, M.; Okada, K.; Tokoroyama, T. *J. Chem. Soc., Chem. Commun.* **1987**, 358.
13. Aizpurua, J. M.; Cossio, F. P.; Palomo, C. *J. Org. Chem.* **1986**, *51*, 4941.
14. Fujii, T.; Saito, T.; Sakuma, T.; Minami, M.; Inoue, I. *Heterocycles*, **1981**, *16*, 215.
15. Iio, H.; Asao, K.; Tokoroyama, T. *J. Chem. Soc., Chem. Commun.* **1985**, 774.
16. It has been reported¹⁵ that the reaction of **13** with **14** produces **15** and **16** in a ratio of ~1:4.4. We have been unable to reproduce this claim. Our experiments consistently produced mixtures of **15** and **16** in a ratio of ~4:5.
17. It has been reported¹⁵ that the conversion of **16** into (-)-**1** can be effected by treatment of **16** with zinc dust in aqueous acetic acid at 60°C. In our hands, repeated attempts to carry out this reaction under these (or similar) conditions gave none of the desired product **1**. The reason(s) underlying our inability to achieve the reported result is (are) unclear. In view of these difficulties, the new method involving an electrochemical protocol was developed.
18. Impure samples of (-)-agelastine B were obtained from Dr. D. J. Faulkner and Dr. R. J. Andersen. Purification of this material by reverse phase HPLC (C₁₈) (MeCN-0.2 M aqueous NaCl) provided the pure natural product. We thank Drs. Faulkner and Andersen for their assistance.

(Received in USA 9 July 1992; accepted 19 August 1992)